Bohlmann L et al ( the QU group in Dec 2018 ): "In high-income...

Bohlmann L et al ( the QU group in Dec 2018 ):
"In high-income settings such as the United States, reports estimate that more than 2 million antibiotic-resistant infections occur per annum with a death toll of 23,000 at a direct cost of $20 billion (3)".
"Here we reveal that the safe-for-human-use ionophore PBT2, in combination with zinc, possesses antibacterial activity and at subinhibitory concentrations reverses Gram-positive bacterial resistance against a number of important antibiotics. The mechanism of action underlying this effect appears to be associated with dysregulation of transition metal ion homeostasis and profound disruption of essential virulence and metabolic systems, all of which may weaken the capacity of these bacterial pathogens to cause infection. Effects on antibiotic resistance were not universal. For instance, erythromycin resistance was reversed in MRSA but not in GAS. PBT2 is a safe-for-human-use ionophore that has progressed to phase 2 human clinical trials (9, 10). Zinc is used as a nutritional supplement and homeopathic remedy, and here we show that the delivery of zinc using the ionophore PBT2 can reduce the concentration of zinc required for efficacy to levels that are tolerated physiologically (30). Taken together, these data demonstrate a new paradigm whereby destabilizing bacterial physiology may circumvent the antibiotic resistance problem, by rescuing the function of antibiotics to which bacteria have become resistant".

IMO we need some human studies before PBT2 is on the market, but this indication is most likely how PBT2 gets there. This market could be bigger for ATH than PBT434 in MSA but it is too early to say almost anything today. So many things are open.